Specifically, the incidence of BMs in EGFR mutant tumors can reach up to 70% during the whole course of the disease, in contrast to 38% observed among patients with EGFR—wt NSCLC [131]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.